Barlesi F, et al. CheckMate 817: First-line nivolumab + ipilimumab in patients with ECOG PS 2 and other special populations with advanced NSCLC. Abstract OA04.02. WCLC 2019, 7-10 september, Barcelona, Spanje.
Gestage groei aantal patiënten met kanker in Nederland
feb 2017 | Borstkanker, Longoncologie, Maag-darm-leveroncologie